Polydrug Use Among People Who Use Opioids, National Survey on Drug Use and Health 2002 to 2017

Total Page:16

File Type:pdf, Size:1020Kb

Polydrug Use Among People Who Use Opioids, National Survey on Drug Use and Health 2002 to 2017 University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 5-2019 Polydrug use among people who use opioids, national survey on drug use and health 2002 to 2017. Diana Kuo Stojda University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Epidemiology Commons Recommended Citation Stojda, Diana Kuo, "Polydrug use among people who use opioids, national survey on drug use and health 2002 to 2017." (2019). Electronic Theses and Dissertations. Paper 3208. https://doi.org/10.18297/etd/3208 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The nivU ersity of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The nivU ersity of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. POLYDRUG USE AMONG PEOPLE WHO USE OPIOIDS, NATIONAL SURVEY ON DRUG USE AND HEALTH 2002 to 2017 By Diana Kuo Stojda BS, The University of North Carolina – Chapel Hill, 2012 MPH, Boston University, 2007 BS, University of Connecticut, 2005 BA, University of Connecticut, 2005 A Dissertation Submitted to the Faculty of the School of Public Health and Information Sciences of the University of Louisville in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Public Health Sciences Department of Epidemiology and Population Health University of Louisville Louisville, Kentucky May 2019 Copyright 2019 by Diana K. Stojda All rights reserved POLYDRUG USE AMONG PEOPLE WHO USE OPIOIDS, NATIONAL SURVEY ON DRUG USE AND HEALTH 2002 to 2017 By Diana Kuo Stojda BS, The University of North Carolina – Chapel Hill, 2012 MPH, Boston University, 2007 BS, University of Connecticut, 2005 BA, University of Connecticut, 2005 A Dissertation Approved on April 15, 2019 by the following Dissertation Committee Richard N. Baumgartner, Ph.D. Martin T. Hall, Ph.D., MSSW Nicholas Peiper, Ph.D., MPH Kira C. Taylor, Ph.D., MS Anne Baber Wallis, Ph.D., MHS ii ACKNOWLEDGMENTS “No one is useless in this world who lightens the burdens of another.” - Charles Dickens Those who know me well, know that I’ve been a student longer than I’ve been a working professional. The journey to obtaining my doctorate was a long and crazy one, with emotional ups and downs, but the one aspect of this journey that has helped me hold on to my sanity was the support of my family, friends, school colleagues, and everyone else who contributed in some way for me to realize my dream of lightening the burdens of others. To my parents, I thank you for supporting me emotionally (and financially!) in my academic pursuits; to my loving husband, Piotr, for putting up with the long distance and time apart; to my closest childhood friends, Christine Ku and Maria Shi, for their emotional comfort during times of deep stress; to all faculty and staff at the School of Public Health and Information Sciences who I have gotten to know throughout my time here; and to my partners in crime at UofL, Chisom Odoh and Colette Davis, for their friendship and emotional support while trying to finish the doctoral program. And finally, to my fantastic dissertation committee members: Drs. Richard Baumgartner, Martin Hall, Nicholas Peiper, Kira Taylor, and Anne Wallis, thank you all for giving me your time, energy, and expertise in making this dissertation a reality. iii ABSTRACT POLYDRUG USE AMONG PEOPLE WHO USE OPIOIDS, NATIONAL SURVEY ON DRUG USE AND HEALTH 2002 to 2017 Diana K. Stojda April 15, 2019 Introduction: Mortality due to overdose has been increasing since 2010 in the U.S., with an increase in the reported use of heroin and co-use of heroin and prescription opioids. Trends and correlates of polydrug use need to be analyzed to propose policies to reduce overdose risk. The overall objective of this study is to characterize high-risk polydrug groups among people who use opioids (PWUO) to understand the patterns of co-used substances and overdose risk factors. Methods: Publicly available data from the 2002-2017 National Survey on Drug Use and Health were analyzed to obtain weighted prevalence rates and trends for PWUO groups, core substance use among each group, as well as polydrug latent classes. Trend analyses consisted of Rao-Scott Chi-square (χ2) tests and joinpoint regression modeling. Multinomial logistic regression was used to determine associations between latent class membership and correlates such as sociodemographic factors, past year opioid use disorder (OUD) and residential transience. Results: Overall prevalence of all individuals who reported the use of either a prescription pain reliever (PPR) or heroin in the past month has declined since 2006, however, the prevalence of the combination opioid use group has been increasing since iv 2002. Multiple substance use by the past month combination opioid use group was substantially greater than those who exclusively used PPR or heroin in the past month, a finding that aligns with past research. Although it was hypothesized the combination opioid class would be characterized as having the highest risk of past year OUD, this was not the case; the Class with the highest adjusted odds of having past year OUD had the highest probability of reporting the past month use of heroin, marijuana, and other illicit substances [aOR (95% CI): 11.03 (6.46, 18.82)]. Conclusion: The increasing prevalence of polydrug use populations among people who use opioids, particularly those who have reported heroin use, underscores the need for prompt action from local, state, and federal stakeholders to pursue more aggressive action to stem the opioid crisis. Policies should conform to a unified public health framework, (e.g., Cascade of Care) and address both individual- and population-level strategies. v TABLE OF CONTENTS Page ACKNOWLEDGMENTS ................................................................................................. iii ABSTRACT ....................................................................................................................... iv LIST OF TABLES ............................................................................................................. ix LIST OF FIGURES ........................................................................................................... xi CHAPTER I: INTRODUCTION AND STUDY OVERVIEW Historical Overview of Opioid Use in the United States ...............................................1 Changing Trends of Prescription Opioid Misuse and Heroin Use in the United States, 2008 to 2014 .......................................................................................................4 Defining Polydrug Use ..................................................................................................5 Rationale and Significance of Study ..............................................................................6 Objective and Specific Aims .........................................................................................8 Hypotheses Testing for Aim 3 .....................................................................................10 Overview of the Present Study ....................................................................................11 CHAPTER II: LITERATURE REVIEW Introduction ..................................................................................................................13 Opioid Literature from 1970 to 1990 ...........................................................................13 Opioid Literature after 1990 ........................................................................................15 vi Epidemiology of People Who Use Opioids .................................................................16 Literature on Polydrug use in PWUO ..........................................................................23 Drug, Set, and Setting Conceptual Framework ............................................................27 Drug Factors: Commonly Co-used Substances in PWUO ..........................................28 Set Factors: Individual Level Characteristics Associated with Opioid Misuse ...........40 Setting Factors: Environmental Characteristics Associated with Opioid Misuse ........46 What This Study Contributes .......................................................................................48 CHAPTER III: RESEARCH DESIGN AND METHODOLOGY Introduction ..................................................................................................................50 National Survey of Drug Use and Health (2002-2017) ...............................................50 The Current Study: Polydrug Use in PWUO, 2002-2017............................................57 Data Analysis Methods ................................................................................................70 CHAPTER IV: RESULTS Aim 1 Results ...............................................................................................................83 Aim 2 Results .............................................................................................................121 Aim 3 Results .............................................................................................................131 CHAPTER V: DISCUSSION Longitudinal Prevalence of People Who Use Opioids and Their
Recommended publications
  • Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs
    SMOKING CEssATION TREATMENT AT SUBSTANCE ABUSE REHABILITATION PROGRAMS Malcolm S. Reid, PhD, New York University School of Medicine, Department of Psychiatry; Jeff Sel- zer, MD, North Shore Long Island Jewish Healthcare System; John Rotrosen, MD, New York University School of Medicine, Department of Psychiatry Cigarette smoking is common among persons with drug and alcohol n Nicotine is a highly use disorders, with prevalence rates of 80-90% among patients in sub- addictive substance stance use disorder treatment programs. Such concurrent smoking may that meets all of produce adverse behavioral and medical problems, and is associated the criteria for drug with greater levels of substance use disorder. dependence. CBehavioral studies indicate that the act of cigarette smoking serves as a cue for drug and alcohol craving, and the active ingredient of cigarettes, nicotine, serves as a primer for drug and alcohol abuse (Sees and Clarke, 1993; Reid et al., 1998). More critically, longitudinal studies have found tobacco use to be the number one cause of preventable death in the United States, and also the single highest contributor to mortality in patients treated for alcoholism (Hurt et al., 1996). Nicotine is a highly addictive substance that meets all of the criteria for drug dependence, and cigarette smoking is an especially effective method for the delivery of nicotine, producing peak brain levels within 15-20 seconds. This rapid drug delivery is one of a number of common properties that cigarette smok- ing shares with hazardous drug and alcohol use, such as the ability to activate the dopamine system in the reward circuitry of the brain.
    [Show full text]
  • Substance Use Resources for Grades 7-12
    1 Substance Use Resources for Grades 7-12 Online Resource Library Search: https://www.voa-dakotas.org/resource-library Addiction: page 1 Alcohol: page 1 Drugs: page 4 Vaping/tobacco: page 10 Addiction Addiction and the Human Brain o DVD, 2006, HRM, 27 minutes, Grades 7-12 o Drug addiction is a disease of the brain and teens are at highest risk for acquiring this disease. This DVD explains the changes to the brain caused by prolonged use of drugs and shows why voluntary drug use eventually becomes involuntary and compulsive. Studies indicate that drugs affect the developing brain more than the brain of someone more mature, thus putting teens at a higher risk of addiction. Interviews with recovering teen addicts, an addiction counselor, and brain experts and researchers provide sobering considerations to viewers. Pre- and Post-tests are included. How Addiction Hijacks the Brain o DVD, 2016, HRM, CC, 24 minutes, Grades 7-College o This film drives home the message that drug and alcohol addiction are a disease of the brain and that teens are at highest risk for acquiring this disease. Leading scientists detail how drugs like heroin, nicotine, cocaine and marijuana change the brain, subvert the way it registers pleasure, and corrupt learning and motivation. Young recovering addicts provide a human face to the effects of drugs and alcohol as they describe how addiction involves intense craving for a drug and loss of control over its use. Viewers also learn that the brain’s plasticity, or ability to change, offers hope for addicts that they can turn their lives around.
    [Show full text]
  • 2019 Ministerial Declaration
    COMMISSION ON NARCOTIC DRUGS VIENNA IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Commission on Narcotic Drugs IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS Vienna, 2019 © United Nations, July 2019. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Contents 1. Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem ...............................1 2. Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” ..................................................9 3. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem ...............................35 4.
    [Show full text]
  • Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
    Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
    Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul­ stance use was considered a potential the most common substance use nerability may be located on chromo­ trigger for the primary addiction.
    [Show full text]
  • Vol. 1, Issue 1
    Methamphetamine Topical Brief Series: Vol. 1, Issue 1 What is countries involved in World War II provided amphetamine to soldiers Methamphetamine? for performance enhancement and the drug was used by “actors, artists, Methamphetamine is an addictive, athletes, politicians, and the public stimulant drug that affects the alike.”5 central nervous system. It is typically used in powder or pill form and can By the 1960s, media coverage be ingested orally, snorted, smoked, began drawing simplistic, negative or injected. Methamphetamine is connections between amphetamine known as meth, blue, ice, speed, and and crime, and government officials 1 crystal among other names. The term discussed public safety and drugs amphetamine has been used broadly as a social concern.6 Over-the- to refer to a group of chemicals that counter amphetamines were have similar, stimulating properties available until 1959,7 and by 1970 and methamphetamine is included in all amphetamines were added to 2 this group. According to the National the controlled substances list as Institute on Drug Abuse (NIDA), Schedule II drugs. Schedule II drugs “Methamphetamine differs from required a new prescription with amphetamine in that, at comparable each fill and strict documentation doses, much greater amounts of the by doctors and pharmacists.8 drug get into the brain, making it a The reduction in a legal supply 3 more potent stimulant.” of amphetamine led to increased black-market production and sale From the 1930s to the 1960s, of various types of amphetamine U.S. pharmaceutical
    [Show full text]
  • Cocaine Use Disorder
    COCAINE USE DISORDER ABSTRACT Cocaine addiction is a serious public health problem. Millions of Americans regularly use cocaine, and some develop a substance use disorder. Cocaine is generally not ingested, but toxicity and death from gastrointestinal absorption has been known to occur. Medications that have been used as substitution therapy for the treatment of a cocaine use disorder include amphetamine, bupropion, methylphenidate, and modafinil. While pharmacological interventions can be effective, a recent review of pharmacological therapy for cocaine use indicates that psycho-social efforts are more consistent over medication as a treatment option. Introduction Cocaine is an illicit, addictive drug that is widely used. Cocaine addiction is a serious public health problem that burdens the healthcare system and that can be destructive to individual lives. It is impossible to know with certainty the extent of use but data from public health surveys, morbidity and mortality reports, and healthcare facilities show that there are millions of Americans who regularly take cocaine. Cocaine intoxication is a common cause for emergency room visits, and it is one drug that is most often involved in fatal overdoses. Some cocaine users take the drug occasionally and sporadically but as with every illicit drug there is a percentage of people who develop a substance use disorder. Treatment of a cocaine use disorder involves psycho-social interventions, pharmacotherapy, or a combination of the two. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com Pharmacology of Cocaine Cocaine is an alkaloid derived from the Erthroxylum coca plant, a plant that is indigenous to South America and several other parts of the world, and is cultivated elsewhere.
    [Show full text]
  • Synthetic Drugs: Overview and Issues for Congress
    Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013.
    [Show full text]
  • Epidemic of Prescription Drug Overdose in Ohio
    EPIDEMIC OF PRESCRIPTION There were more deaths in 2008 and 2009 in Ohio from D RUG OVERDOSE IN OHIO unintentional drug overdose than from DID YOU KNOW? motor vehicle In 2007, unintentional drug poisoning became the leading crashes! cause of injury death in Ohio, surpassing motor vehicle crashes and suicide for the first time on record. This trend continued in 2009. (See Figure 1) Among the leading causes of injury death (see below), unintentional poisonings increased from the cause of the fewest number of annual deaths in 1999 (369 deaths) to the greatest in 2009 (1,817).i (See Figure 2) From 1999 to 2009, Ohio’s death rate due to unintentional drug poisonings increased 335 percent, and the increase in deaths has been driven largely by prescription drug overdoses. In Ohio, there were 327 fatal unintentional drug overdoses in 1999 growing to 1,423 annual deaths in 2009. On average, from 2006 to 2009, approximately four people died each day in Ohio due to drug overdose.v Figure 1. Number of deaths from MV traffic Figure 2 . Percent change in the number of deaths for and unintentional drug poisonings by year, the leading causes of injury, Ohio 1999-20091,2 Ohio, 2000-20091,2 1800 all unintentional 39% 1600 firearm related 15% 1400 1200 homicide 34% 1000 unintentional suicide 17% 800 poisoning 600 unintentional poisoning 301% unt MV traffic Number of deathsNumber 400 unt MV traffic -31% 200 unintentional falls 100% 0 -100% 0% 100% 200% 300% 400% Percent change from 2000-2009 Year 1Source: Ohio Department of Health, Office of Vital Statistics; 2 Unintentional Poisoning includes non-drug and drug-related poisoning.
    [Show full text]
  • Suicides Due to Alcohol And/Or Drug Overdose
    Suicides Due to Alcohol and/or Drug Overdose A Data Brief from the National Violent Death Reporting System National Center for Injury Prevention and Control Division of Violence Prevention Background Suicide occurs when a person ends his or her own life. It is the 11th leading cause of death among NVDRS is a state-based system for Americans, and every year more than 33,000 providing detailed information about people end their own lives. Suicide is found in violent deaths, such as when, where, every age, racial, and ethnic group to differing and how they happen and other possible degrees (1). contributing factors. This information can be used to monitor homicides and There are a number of factors that increase the suicides and design and evaluate prevention likelihood a person will take his or her own life; strategies. Benefits of NVDRS include the one of these is abusing substances such as alcohol following: and drugs (1). Alcohol and drug abuse are second only to depression and other mood disorders as• Linked records describing the detailed the most frequent risk factors for suicidal behavior circumstances that may contribute to a (2, 3). Alcohol and some drugs can result in a loss violent death of inhibition, may increase impulsive behavior, can lead to changes in the brain that result in • Identification of violent deaths occurring depression over time, and can be disruptive to together to help describe the circumstance relationships— resulting in alienation and a loss of multiple homicides or homicide- of social connection (4). Furthermore, excessive suicides acute drug and/or alcohol ingestion could result in death.
    [Show full text]
  • The Biden-Harris Administration's Statement of Drug Policy Priorities
    EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF NATIONAL DRUG CONTROL POLICY Washington, DC 20503 The Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One The overdose and addiction crisis has taken a heartbreaking toll on far too many Americans and their families. Since 2015, overdose death numbers have risen 35 percent, reaching a historic high of 70,630 deaths in 2019.1 This is a greater rate of increase than for any other type of injury death in the United States.2 Though illicitly manufactured fentanyl and synthetic opioids other than methadone (SOOTM) have been the primary driver behind the increase, overdose deaths involving cocaine and other psychostimulants, like methamphetamine,3 have also risen in recent years, particularly in combination with SOOTM. New data suggest that COVID-19 has exacerbated the epidemic,4, 5 and increases in overdose mortality6 have underscored systemic inequities in our nation’s approach to criminal justice and prevention, treatment, and recovery. President Biden has made clear that addressing the overdose and addiction epidemic is an urgent priority for his administration. In March, the President signed into law the American Rescue Plan, which appropriated nearly $4 billion to enable the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to expand access to vital behavioral health services. President Biden has also said that people should not be incarcerated for drug use but should be offered treatment instead. The President has also emphasized the need to eradicate racial, gender, and economic inequities that currently exist in the criminal justice system.
    [Show full text]